Abstract
In the present study, we have synthesized a series of novel 2-(3-substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones by the reaction of 3-(substituted)-2-hydrazino-quinazoline-4(3H)-ones with phthalic anhydride. The starting material 3-(substituted)-2-hydrazino-quinazolin-4(3H)-ones were synthesized from various primary amines. All the synthesized compounds were screened for their antitubercular, anti-HIV and antibacterial activity against different gram positive and gram negative strains by agar dilution method. Among the test compounds, 2-(3-(4-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-dione (QCT7) shown most potent antibacterial activity against E. coli, and S. aureus with the MIC of 3 µg/mL. The compound QCT7 exhibited the antitubercular activity with the MIC of 25 µg/mL and anti-HIV activity with the EC50 of 43.68 µM against HIV1 and HIV2 and offers potential lead for further optimization and development to new antitubercular and anti-HIV agents. The results obtained from this study confirm that the synthesized and biologically evaluated quinazolines showed promising antimicrobial, antitubercular and anti-HIV activities and are new scaffolds for antimicrobial activity.
Similar content being viewed by others
REFERENCES
World Health Organization, Global Tuberculosis Report 2018, Geneva, Switzerland: World Health Organization, 2018.
Balcha, T.T., Skogmar, S., Sturegård, E., Björkman, P., Winqvist, N., Glob. Health Action, 2015, vol. 8, pp. 27 048–27 049. https://doi.org/10.3402/gha.v8.27048
Reid, M.J. and Shah, N.S., Lancet Infect. Dis., 2009, vol. 9, p. 173. https://doi.org/10.1016/S1473-3099(09)70043-X
World Health Organization Tuberculosis. https://www.who.int/tb/en/. Accessed March 17, 2019.
Alagarsamy, V., Chitra, K., Saravanan, G., Solomon, V. R., Sulthana, M.T., and Narendhar, B., Eur. J. Med. Chem., 2018, vol. 151, pp. 628–685. https://doi.org/10.1016/j.ejmech.2018.03.076
Hameed, A., Al-Rashida, M., Uroos, M., Ali, S.A., Ishtiaq, M., and Khan, K.M., Expert Opin.Ther. Pat., 2018, vol. 28, pp. 281–297. https://doi.org/10.1080/13543776.2018.1432596
Pavan, F.R., Da S Maia, P.I., Leite, S.R., Deflon, V.M., Batista, A.A., Sato, D.N., Franzblau, S.G., and Leite, C.Q., Eur. J. Med. Chem., 2010, vol. 45, pp. 1898–1905. https://doi.org/10.1016/j.ejmech.2010.01.028
Güzel, O., Karali, N., and Salman. A., Bioorg. Med. Chem., 2008, vol. 16, pp. 8976–8987. https://doi.org/10.1016/j.bmc.2008.08.050
Karali, N., Gürsoy, A., Kemirli, F., Shvets, N., Kaynak, F.B., Ozbey, S., Kovalishyn, V., and Dimoglo, A., Bioorg. Med. Chem., 2007, vol. 15, pp. 5888–5904. https://doi.org/10.1016/j.bmc.2007.05.063
Sriram, D., Yogeeswari, P., Thirumurugan, R., and Pavana, R.K., J. Med. Chem., 2006, vol. 49, pp. 3448–3450. https://doi.org/10.1021/jm060339h
Sriram, D., Yogeeswari, P., Dhakla, P., Senthilkumar, P., Banerjee, D., Manjashetty, T.H., Bioorg. Med. Chem. Lett., 2009, vol. 19, pp. 1152–1154. https://doi.org/10.1016/j.bmcl.2008.12.088
Saripinar, E., Güzel, Y., Patat, S., Yildirim, I., Akçamur, Y., and Dimoglo, A.S., Arzneimittelforschung, 1996, vol. 46, pp. 824–828.
Milczarska, B., Foks, H., Sokołowska, J., Janowiec, M., Zwolska, Z., and Rzejczyk, Z., Acta Pol. Pharm., 1999, vol. 56, pp. 121–126.
Turan-Zitouni, G., Ozdemir, A., Kaplancikli, Z.A., Benkli, K., Chevallet, P., and Akalin, G., Eur. J. Med. Chem., 2008, vol. 43, pp. 981–985. https://doi.org/10.1016/j.ejmech.2007.07.001
Peya, S.N., Smitha, S., Jyoti, M., and Sridhar, S.K., Acta Pharmaceutica, 2005, vol. 55, pp. 27–46.
Meunier. B., Acc. Chem. Res., 2008, vol. 41, pp. 69–77. https://doi.org/10.1021/ar7000843
Alagarsamy, V., Solomon, V.R., Sheorey, R.V., and Jayakumar. R., Chem. Biol. Drug. Des., 2009, vol. 73, pp. 471–479. https://doi.org/10.1111/j.1747-0285.2009.00794.x
Alagarsamy, V., Appani, R., Sulthana, M.T., Narendar, B., and Solomon, V.R., J. Chilean Chem. Soc., 2016, vol. 61, pp. 2856–2860. https://doi.org/10.4067/S0717-97072016000200002
Sheory, R.V., Thangathiruppathy, A., and Alagarsamy, V., Trop. J. Pharm Res., 2013, vol. 12, pp. 583–589. https://doi.org/10.4314/tjpr.v12i4.21
Alagarsamy V., Solomon V.R., and Dhanabal, K., Bioorg. Med. Chem., 2007, vol. 5, pp. 235–224. https://doi.org/10.1016/j.bmc.2006.09.065
Gobinath, M., Subramanian, N., Alagarsamy, V., Nivedhitha S., and Solomon, V.R., Trop. J. Pharm. Res., 2015, vol. 14, pp. 271–277. https://doi.org/10.4314/tjpr.v14i2.12
Alagarsamy, V., Shankar, D., Murugan, M., Siddiqui, A.A., and Rajesh, R., Arch. Pharm. Chem. Life Sci., 2007 vol. 340, pp. 41–46. https://doi.org/10.1002/ardp.200600189
Alagarsamy, V., Giridhar, R., and Yadav, M.R., J. Pharm. Pharmacol., 2006, vol. 58, pp. 1249–1255. https://doi.org/10.1211/jpp.58.9.0012
Gobinath, M., Subramanian, N., Ruckmani, K., and Alagarsamy, V., Int. J. Drug Discov., 2011, vol. 2, pp. 642–647.
Sriram, D., Yogeeswari, P., Basha, J.S., Radha, D.R., and Nagaraja, V., Bioorg. Med. Chem., 2005, vol. 13, pp. 5774–5778.https://doi.org/10.1016/j.bmc.2005.05.063
Shanmugavelan, P., Nagarajan, S., Sathishkumar, M., Ponnuswamy, A., Yogeeswari, P., and Sriram, D., Bioorg. Med. Chem. Lett., 2011, vol. 21, pp. 7273–7276. https://doi.org/10.1016/j.bmcl.2011.10.048
Kunes, J., Bazant, J., Pour, M., Waisser, K., Slosárek, M., and Janota, J., IL Farmaco, 2000, vol. 55, pp. 725–729. https://doi.org/10.1016/s0014-827x(00)00100-2
Pauwels, R., Clercq, E. De., Desmyter, J., Balzarini, P., Goubabu, P., Herdesijin, P., Verhaughe, H., and Veputle, M. J., Virol. Methods, 1987, vol. 16, pp. 171–185. https://doi.org/10.1016/0166-0934(87)90002-4
Barry, A., Antibiotics in Laboratory Medicine, 5th ed., Baltimore, MD: William Wilkins, 1991, vol. 1.
Peya, S.N., Sriram, D., Nath, G., and De Clercq, E., IL Farmaco, 1999, vol. 54, pp. 624–628. https://doi.org/10.1016/s0014-827x(99)00075-0
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
COMPLIANCE WITH ETHICAL STANDARDS
This article does not contain studies that use humans and animals as objects of research.
Conflict of Interests
The authors declare no conflict of interest.
Additional information
Corresponding author: phone: +91 8455-230690; fax: +91 8455-230555.
Rights and permissions
About this article
Cite this article
Sulthana, M.T., Chitra, K., Alagarsamy, V. et al. Anti-HIV and Antibacterial Activities of Novel 2-(3-Substituted-4-oxo-3,4-dihydroquinazolin-2-yl)-2,3-dihydrophthalazine-1,4-diones. Russ J Bioorg Chem 47, 112–121 (2021). https://doi.org/10.1134/S1068162021010246
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1068162021010246